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Deciphering Digital Dermatitis
Abstract
Bovine digital dermatitis (DD) is a leading cause of lameness in dairy cattle throughout the world. Despite
more than 40 years of research, the definitive etio- logic agent associated with the disease pro- cess is still
unknown. Previous studies have demonstrated that multiple bacterial species are associated with lesions, with
spirochetes being the most reliably identified organism.
According to the most recent National Animal Health Monitoring System survey of U.S. dairy farms, lameness
is the second most common health problem identified in dairy cattle. DD was found to be the primary cause
of lameness within the study herds, account- ing for 61.8% of the lameness in bred heifers and 49.1% of the
lameness in cows. Recently, the condition has become increasingly com- mon in feedyard cattle as well,
particularly in heavy cattle nearing slaughter weights, although it can be seen in cow–calf opera- tions as well.
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Bovine digital dermatitis (DD) is a lead-ing cause of lameness in dairy cattle throughout the world. Despite more 
than 40 years of research, the definitive etio-
logic agent associated with the disease pro-
cess is still unknown. Previous studies have 
demonstrated that multiple bacterial species 
are associated with lesions, with spirochetes 
being the most reliably identified organism. 
According to the most recent National 
Animal Health Monitoring System survey of 
U.S. dairy farms, lameness is the second most 
common health problem identified in dairy 
cattle. DD was found to be the primary cause 
of lameness within the study herds, account-
ing for 61.8% of the lameness in bred heifers 
and 49.1% of the lameness in cows. Recently, 
the condition has become increasingly com-
mon in feedyard cattle as well, particularly 
in heavy cattle nearing slaughter weights, 
although it can be seen in cow–calf opera-
tions as well. 
A PROMINENT BUT ELUSIVE DISEASE
Our research team at Iowa State University (ISU) has con-
ducted a series of studies on the pathogens, disease processes 
and effects of DD in dairy and beef cattle, which have led to 
some key insights on the disease including:
9 DD is a progressive, polybacterial disease process, and spiro-
chetes of the Treponema genus, which are commonly associated 
with DD, typically are not predominant pathogens in early 
stage DD lesions. 
9 A DD scoring system can be useful in evaluating and monitor-
ing disease progression and the success of interventions in a herd, 
and in decision making regarding treatment and control strategies.
9 Lameness incidence, measured by locomotion scoring, is 
not necessarily a reliable indicator of the overall incidence of 
DD in a herd. Many lesions are locally painful to the touch but 
result in minimal change in locomotion score.
Bovine DD was first described in 1974. The first morpho-
logical description of DD as an ulcerative disease of the bovine 
coronary band occurred at the 8th International Meeting on 
Diseases of Cattle in Milan, Italy. The first etiologic descriptions 
of the disease were published in 1992 and were soon followed by 
a report describing the isolation and identification of an anaerobic 
spirochete, believed to be a Treponema spp., in the lesions. 
Since that time, a number of additional papers have been 
published demonstrating the association of the lesions with 
additional bacteria, including Bacteroides spp. (now called Por-
phyromonas spp.), Campylobacter spp. and Borrelia spp., as well 
as viral etiologies. While there is a consistent presence of several 
Treponema phylotypes in DD lesions, attempts to induce disease 
by skin inoculation with pure cultures of these microorganisms 
have largely failed to result in significant disease in a majority of 
the animals inoculated. Furthermore, there is evidence to sug-
gest that the clinical use of vaccines against spirochetes provides 
limited protection against the disease process. 
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DECIPHERING  
DIGITAL DERMATITIS
Research implicates multiple pathogens, with etiology changing 
through stages of disease progression. 
BY PAUL J. PLUMMER, DVM, PH.D.; JAN K. 
SHEARER, DVM, M.S., COLLEGE OF VETERI-
NARY MEDICINE, IOWA STATE UNIVERSITY
The Iowa State University lameness team includes, from left: Drs. John Coatney, 
Jan Shearer, Paul Plummer and Adam Krull. Members not pictured include Patrick 
Gorden and Vicki Cooper.
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Our team recently reported a study detailing the deep sequenc-
ing-based metagenomic evaluation of 48 staged DD biopsy 
specimens collected during a three-year longitudinal study of 
disease progression. Over 175 million sequences were evaluated 
by utilizing both shotgun and 16S metagenomic techniques.
Based on the shotgun sequencing results, there was no 
evidence of a fungal or DNA viral etiology. The bacterial 
microbiota of biopsy specimens progresses through a systematic 
series of changes that correlate with the novel morphological 
lesion-scoring system developed as part of this project. This 
scoring system was validated, as the microbiota of each stage was 
statistically significantly different from those of other stages (P 
< 0.001). The microbiota of control biopsy specimens were the 
most diverse and became less diverse as lesions developed. 
Although Treponema spp. predominated in the advanced 
lesions, they were in relatively low abundance in the newly 
described early lesions that are believed to be associated with the 
initiation of the disease process. The consortium of Treponema
spp. identified at the onset of disease changes considerably as the 
lesions progress through the morphological stages identified.
The results of this study support the hypothesis that DD is a 
polybacterial disease process and provide unique insights into 
the temporal changes in bacterial populations throughout the  
development of lesions.
BACTERIAL CONNECTION
The widely observed and consistent clinical response to topical 
antibiotics suggests a bacterial agent as the true etiology of the 
disease. The association of DD lesions with a variety of bacterial 
agents, the response of the lesions to antibiotics and the failure 
to induce disease or protect against it using monovalent vaccines 
strongly suggest that DD is a polymicrobial disease process. 
SCORING SYSTEM FOR DD 
In our three-year study, the ISU team used the Iowa DD scoring 
system to evaluate the epidemiology of natural lesion develop-
ment by digitally photographing the rear legs of a cohort of 
dairy cows over a three-year period. Sixty-one adult Holstein 
dairy cows were monitored for 1,032 cow foot-months, during 
which they were not exposed to any DD-control measures. The 
incidence rate of lesion development was four lesions per 100 
cow foot-months, with the average time for a lesion to develop 
being 133 days.  
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The use of lameness in herds as a proxy for the  
prevalence of DD would underestimate the number  
of cows affected with DD, as we observed that the  
majority of clinical lesions fail to induce lameness.
150 mg/mL ANTIMICROBIAL
NADA 141-328, Approved by FDA
For subcutaneous injection in beef and non-lactating dairy cattle 
only. Not for use in female dairy cattle 20 months of age or older or 
in calves to be processed for veal.
Caution: Federal (USA) law restricts this drug to use by or on the 
order of a licensed veterinarian.
READ ENTIRE BROCHURE CAREFULLY BEFORE USING THIS 
PRODUCT.
INDICATIONS
ZACTRAN is indicated for the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica, Pasteurella 
multocida, Histophilus somni and Mycoplasma bovis in beef and 
non-lactating dairy cattle. ZACTRAN is also indicated for the control 
of respiratory disease in beef and non-lactating dairy cattle at high 
risk of developing BRD associated with Mannheimia haemolytica 
and Pasteurella multocida.
CONTRAINDICATIONS
As with all drugs, the use of ZACTRAN is contraindicated in animals 
previously found to be hypersensitive to this drug.
WARNING: FOR USE IN CATTLE ONLY. NOT FOR USE IN HUMANS. 
KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. NOT 
FOR USE IN CHICKENS OR TURKEYS.
The material safety data sheet (MSDS) contains more detailed 
occupational safety information. To report adverse effects, obtain 
an MSDS or for assistance, contact Merial at 1-888-637-4251.
RESIDUE WARNINGS: Do not treat cattle within 
35 days of slaughter. Because a discard time in 
milk has not been established, do not use in 
female dairy cattle 20 months of age or older. A 
withdrawal period has not been established for 
this product in pre-ruminating calves. Do not use in 
calves to be processed for veal.
PRECAUTIONS 
The effects of ZACTRAN on bovine reproductive performance, 
pregnancy, and lactation have not been determined. Subcutaneous 
injection of ZACTRAN may cause a transient local tissue reaction 
in some cattle that may result in trim loss of edible tissues at 
slaughter.
ADVERSE REACTIONS
Transient animal discomfort and mild to moderate injection site 
swelling may be seen in cattle treated with ZACTRAN.
EFFECTIVENESS
The effectiveness of ZACTRAN for the treatment of BRD associated 
with Mannheimia haemolytica, Pasteurella multocida and 
Histophilus somni was demonstrated in a field study conducted 
at four geographic locations in the United States.  A total of 497 
cattle exhibiting clinical signs of BRD were enrolled in the study. 
Cattle were administered ZACTRAN (6 mg/kg BW) or an equivalent 
volume of sterile saline as a subcutaneous injection once on 
Day 0. Cattle were observed daily for clinical signs of BRD and 
were evaluated for clinical success on Day 10. The percentage of 
successes in cattle treated with ZACTRAN (58%) was statistically 
significantly higher (p<0.05) than the percentage of successes in 
the cattle treated with saline (19%).
The effectiveness of ZACTRAN for the treatment of BRD associated 
with M. bovis was demonstrated independently at two U.S. study 
sites. A total of 502 cattle exhibiting clinical signs of BRD were 
enrolled in the studies. Cattle were administered ZACTRAN (6 mg/
kg BW) or an equivalent volume of sterile saline as a subcutaneous 
injection once on Day 0. At each site, the percentage of successes 
in cattle treated with ZACTRAN on Day 10 was statistically 
significantly higher than the percentage of successes in the cattle 
treated with saline (74.4% vs. 24% [p <0.001], and 67.4% vs. 
46.2% [p = 0.002]). In addition, in the group of calves treated 
with gamithromycin that were confirmed positive for M. bovis 
(pre-treatment nasopharyngeal swabs), there were more calves at 
each site (45 of 57 calves, and 5 of 6 calves) classified as successes 
than as failures.
The effectiveness of ZACTRAN for the control of respiratory 
disease in cattle at high risk of developing BRD associated 
with Mannheimia haemolytica and Pasteurella multocida was 
demonstrated in two independent studies conducted in the 
United States. A total of 467 crossbred beef cattle at high risk of 
developing BRD were enrolled in the study. ZACTRAN (6 mg/kg 
BW) or an equivalent volume of sterile saline was administered as 
a single subcutaneous injection within one day after arrival. Cattle 
were observed daily for clinical signs of BRD and were evaluated 
for clinical success on Day 10 post-treatment. In each of the two 
studies, the percentage of successes in the cattle treated with 
ZACTRAN (86% and 78%) was statistically significantly higher (p 
= 0.0019 and p = 0.0016) than the percentage of successes in the 
cattle treated with saline (36% and 58%).
Marketed by Merial Limited 
3239 Satellite Blvd., Duluth, GA 30096-4640 U.S.A.
Made in Austria 
®ZACTRAN is a registered trademark of Merial Limited.  
 ©2012 Merial Limited. All rights reserved. Rev. 03/2012
®
(gamithromycin)
The Iowa DD scoring system classiﬁes lesions as: 
Stage 0: Normal skin.
: Early lesions
Stage 1: Initial onset lesions. Stage 1 lesions are character-
ized as small, localized focal to multifocal lesions that have 
failed to coalesce into a continuous lesion that involves the 
majority of the plantar skin adjacent to the interdigital cleft.
Stage 2: Developing lesions. Once the lesions have coalesced 
to involve the majority of the plantar skin adjacent to the 
interdigital cleft they would be characterized as stage 2.
: Active lesions
Stage 3: Lesions associated with clinical disease in the acute 
hyperemic ulcerative form. The transition to stage 3 lesions 
is characterized by the presence of an ulcerated, hyperemic 
circular lesion that has the roughened strawberry-like 
appearance of a classical DD lesion.
Stage 4: Chronic hyperkeratotic form.
Additionally, stages 1 and 2 are subdivided into two subtypes, 
with “A” type lesions being exclusively located in the plantar 
interdigital cleft and having a more ulcerated appearance, and 
“B” type lesions having a thickened, crusted appearance diffusely 
spread across the heel.
Whereas 20% of the 1,678 foot observations exhibited clini-
cal DD lesions, an additional 55% of all observations exhibited 
preclinical stage 1 and 2 lesions that were indicative of DD 
lesion development (having a different microbial population 
than that observed in active lesions). 
Utilizing the dichotomous categorization of preclinical 
lesions in the Iowa DD scoring system, it was found that first-
lactation heifers had a higher rate of the thickened and crusted 
“B” type lesions, whereas the ulcerative “A” type lesions were 
more likely to be identified in multiparous animals.
For clinical DD lesions that received topical treatment, scor-
ing of the post-treatment lesions using the Iowa DD scoring 
system was found to be useful in prognosticating both the risk 
of recrudescence and the time until recrudescence. 
Systemic disease, systemic antibiotic therapy and periparturi-
ent stress were not associated with an increase or decrease in 
DD lesion scores. Treatment with a single topical tetracycline 
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These pictures illustrate the two pre-clinical digital dermatitis lesion types.
wrap was associated with a significant decrease (−1.17) in DD 
lesion score. The results of this study demonstrate that the 
complex morphologic changes associated with DD can be read-
ily classified using the Iowa DD scoring system, and the scores 
can be used to predict and monitor the effects of treatment and 
prevention measures. In some clinical scenarios it is useful to 
simplify lesion scoring by condensing the scores down to early 
lesions (stages 1 and 2) and active lesions (stages 3 and 4).  A 
critical factor in implementing and using a DD scoring system 
on-farm is having a good understanding of how the data will be 
used and what outcomes will be measured.  A variety of scoring 
systems have been developed and have utility in the manage-
ment of DD, and veterinarians and producers are encouraged to 
determine what scoring system best fits their needs.
Our team conducted routine locomotion scoring throughout 
the study to monitor for evidence and severity of lameness. Any 
animal that reached a locomotion score of 4 on the 5-point 
lameness scale, or any animal noted by caretakers as being lame, 
was promptly examined by the study personnel.
If lameness was determined to be associated with DD lesions, 
and no other cause of lameness was observed, treatment with a 
topical tetracycline wrap was initiated. This wrap consisted of 
approximately 5 g of oxytetracycline hydrochloride placed over 
the lesion, then covered with gauze and wrapped with a self-
adherent wrap. 
In this study, we categorized animals into four possible groups 
based on the observed outcome following a single treatment of a 
clinical DD lesion (stage 3 or 4) with a tetracycline wrap. These 
groups were followed for an average of 300 days post treatment 
and were classified as:
1. A lesion that did not respond to treatment (i.e., a lesion of 
stage 3 or 4 did not drop below a stage 3 following treatment).
2. A lesion that responded to treatment (regression to stage 2 
or less) but subsequently returned to a stage 3 or 4 lesion within 
the time of observation, 
3. A lesion that responded to treatment (regression to stage 2 
or less) and remained as a stage 1 or 2 lesion without returning 
to normal skin or returning to a clinical lesion. 
4. A lesion that responded to treatment and returned to 
normal skin. 
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These four outcomes were deemed as nonresponsive to treat-
ment, lesion recrudescence, lesion regression and treatment 
success, respectively. A treatment failure collectively included all 
of the first three categories that did not result in a lesion revert-
ing to normal skin. Importantly, following a single application 
of oxytetracycline we observed an almost 90% treatment failure 
rate when lesions were followed for an extended period of time 
(i.e., the majority redeveloped lesions over the following year). 
The average time to lesion formation was associated with the 
minimum score achieved following treatment. In cases where 
the skin returned to normal (only about 10% of the cases), it 
remained normal throughout the remainder of the follow-up 
period, which averaged 420 days for that group.
The ability for an early lesion to progress to an advanced 
lesion is believed to be inﬂuenced by a variety of factors 
that include:
9 Exposure to and colonization of the early lesion by bacterial 
agents necessary for this transition (i.e., the bacteria that dif-
ferentiate advanced lesions from early lesions based on our prior 
work, described in Krull et al., 2014).
9 Host genetics and immunity.
9 Environmental conditions. 
Clinical experience would also suggest that in a small number 
of dairy herds the only types of DD lesions observed are early 
lesions (stage 1 and 2). At present, it is unclear how the various 
factors described above work together to limit the transition to 
advanced lesions, and additional research to answer this interest-
ing question is warranted.
Several other important observations were noted over the 
course of the three years that have implications as to how we 
view the incidence of DD. The fact that 75% of observations 
had lesion scores greater than zero suggests that when cows are 
not exposed to any DD-prevention measures, the majority of 
feet in farms with endemic DD could develop some level of DD. 
With a smaller portion of those lesions being clinical lesions 
that would be recognized by hoof trimmers and practitioners as 
classic DD lesions, estimates of incidence rates and prevalence 
have the potential to be greatly underestimated in the literature. 
Although we did not directly measure prevalence, our calcula-
tion of prevalence was in line with other studies’ estimates of 
20% to 26% in freestall barns (Cramer et al., 2008). Impor-
tantly, the use of lameness in herds as a proxy for the prevalence 
of DD would underestimate the number of cows affected, as 
we observed that the majority of clinical lesions fail to induce 
lameness. The use of locomotion score as a way to identify cows 
with DD was shown to be very inconsistent, with many cows 
maintaining clinical lesions for months to years without ever 
reaching a stage 4 or 5 locomotion score. This is consistent with 
data from Frankena et al. (2009), in which only 39% of cows 
with severe DD lesions ever showed any sign of lameness.
TREATMENT OPTIONS
Topical antibiotic applications remain the best option for 
controlling and treating active DD lesions. The use of footbaths 
also plays an important role in the control of earlier lesion 
stages and likely minimizes the number of animals that develop 
active mature lesions and become lame. While systemic therapy 
would be far more convenient, there are no controlled studies 
that support the efficacy of parenteral treatment with antibiot-
ics routinely used in bovine practice. This is an area in need of 
further study to confirm the possible benefits of treatment with 
some of the newer long-acting antibiotics. 
Medicated feed also would provide convenience, but no oral 
antibiotics have a claim for controlling or preventing DD, and it is 
illegal to use antibiotics in an extra-label manner in feed. 
In short, based upon available literature and experience, the 
best treatments at the present time are individual treatment 
with topical antimicrobials, topical spray or a well-designed and 
managed footbath. 
Future research into whether more aggressive treatment as 
a means to return DD lesions back to normal skin would be 
beneficial in lowering the recrudescence rate is warranted. Addi-
tionally, further studies evaluating the economics of treating the 
more prevalent preclinical lesions before developing into clinical 
DD lesions should be looked at to reduce lameness and produc-
tion losses associated with clinical lesions.  
More advanced clinical or active DD lesions include mature lesions (left) and a more chronic lesion (right). 
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